The PREDICT study

A randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure

Matthew J. Kuhn, Nan Chen, Dushyant V. Sahani, Dan Reimer, Edwin J.R. Van Beek, Jay Heiken, George J. So

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

OBJECTIVE. The objective of the PREDICT (patients with renal impairment and diabetes undergoing computed tomography) study was to compare the incidence of contrast-induced nephropathy (CIN) after administration of low-osmolar (iopamidol 370, 796 mOsm/ kg) or isoosmolar (iodixanol 320, 290 mOsm/kg) contrast medium in patients with diabetes and chronic kidney disease undergoing CT. SUBJECTS AND METHODS. Two hundred sixty-three patients with moderate to severe chronic kidney disease (estimated glomerular filtration rate [GFR] = 20-59 mL/ min/1.73 m2) and diabetes mellitus were randomized to receive at least 65 mL of iopamidol 370 or iodixanol 320 for a CT procedure. Serum creatinine levels were measured at baseline and 48-72 hours after contrast administration. CIN was defined as an increase in the serum creatinine level after contrast administration of ≥ 25% from the baseline level. The incidence of CIN in the total study population and the incidence of CIN in patients at increased risk for CIN were compared using Fisher's exact test. RESULTS. Two hundred forty-eight patients were included in the CIN analysis: 125 receiving iopamidol 370 and 123 receiving iodixanol 320. Study population demographics were comparable, as was baseline renal function (estimated GFR = 47.6 mL/min/1.73 m2 for the iopamidol 370 group vs 49.9 mL/min/1.73 m 2 for the iodixanol 320 group; p = 0.16). Increases in the serum creatinine value of ≥ 25% occurred in seven patients (5.6%) receiving iopamidol 370 and in six patients (4.9%) receiving iodixanol 320 (95% CI, -4.8% to 6.3%; p = 1.0). The mean serum creatinine change from the baseline level was 0.04 mg/dL in both groups (analysis of covariance, p = 0.80). In patients with a baseline serum creatinine value of ≥ 2.0 mg/dL, baseline estimated GFR of ≤ 40 mL/min/1.73 m2, or those receiving > 140 mL of contrast medium, the incidence of CIN was low and comparable between the two study groups (p = 1.0 in all instances). CONCLUSION. The incidence of CIN in patients with diabetes and chronic kidney disease receiving IV contrast medium was not significantly different after CT using iopamidol 370 or iodixanol 320.

Original languageEnglish (US)
Pages (from-to)151-157
Number of pages7
JournalAmerican Journal of Roentgenology
Volume191
Issue number1
DOIs
StatePublished - Jul 1 2008
Externally publishedYes

Fingerprint

Iopamidol
Contrast Media
Creatinine
Glomerular Filtration Rate
Chronic Renal Insufficiency
Serum
Incidence
Kidney
Population
iodixanol
Diabetes Mellitus
Cohort Studies
Tomography
Demography

Keywords

  • Contrast media
  • Contrast-induced nephropathy
  • CT
  • Diabetes mellitus
  • Iodixanol
  • Iopamidol
  • Kidney disease
  • Renal insufficiency

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

The PREDICT study : A randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. / Kuhn, Matthew J.; Chen, Nan; Sahani, Dushyant V.; Reimer, Dan; Van Beek, Edwin J.R.; Heiken, Jay; So, George J.

In: American Journal of Roentgenology, Vol. 191, No. 1, 01.07.2008, p. 151-157.

Research output: Contribution to journalArticle

Kuhn, Matthew J. ; Chen, Nan ; Sahani, Dushyant V. ; Reimer, Dan ; Van Beek, Edwin J.R. ; Heiken, Jay ; So, George J. / The PREDICT study : A randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. In: American Journal of Roentgenology. 2008 ; Vol. 191, No. 1. pp. 151-157.
@article{0ee29201064c4ac28cce39784a3cb821,
title = "The PREDICT study: A randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure",
abstract = "OBJECTIVE. The objective of the PREDICT (patients with renal impairment and diabetes undergoing computed tomography) study was to compare the incidence of contrast-induced nephropathy (CIN) after administration of low-osmolar (iopamidol 370, 796 mOsm/ kg) or isoosmolar (iodixanol 320, 290 mOsm/kg) contrast medium in patients with diabetes and chronic kidney disease undergoing CT. SUBJECTS AND METHODS. Two hundred sixty-three patients with moderate to severe chronic kidney disease (estimated glomerular filtration rate [GFR] = 20-59 mL/ min/1.73 m2) and diabetes mellitus were randomized to receive at least 65 mL of iopamidol 370 or iodixanol 320 for a CT procedure. Serum creatinine levels were measured at baseline and 48-72 hours after contrast administration. CIN was defined as an increase in the serum creatinine level after contrast administration of ≥ 25{\%} from the baseline level. The incidence of CIN in the total study population and the incidence of CIN in patients at increased risk for CIN were compared using Fisher's exact test. RESULTS. Two hundred forty-eight patients were included in the CIN analysis: 125 receiving iopamidol 370 and 123 receiving iodixanol 320. Study population demographics were comparable, as was baseline renal function (estimated GFR = 47.6 mL/min/1.73 m2 for the iopamidol 370 group vs 49.9 mL/min/1.73 m 2 for the iodixanol 320 group; p = 0.16). Increases in the serum creatinine value of ≥ 25{\%} occurred in seven patients (5.6{\%}) receiving iopamidol 370 and in six patients (4.9{\%}) receiving iodixanol 320 (95{\%} CI, -4.8{\%} to 6.3{\%}; p = 1.0). The mean serum creatinine change from the baseline level was 0.04 mg/dL in both groups (analysis of covariance, p = 0.80). In patients with a baseline serum creatinine value of ≥ 2.0 mg/dL, baseline estimated GFR of ≤ 40 mL/min/1.73 m2, or those receiving > 140 mL of contrast medium, the incidence of CIN was low and comparable between the two study groups (p = 1.0 in all instances). CONCLUSION. The incidence of CIN in patients with diabetes and chronic kidney disease receiving IV contrast medium was not significantly different after CT using iopamidol 370 or iodixanol 320.",
keywords = "Contrast media, Contrast-induced nephropathy, CT, Diabetes mellitus, Iodixanol, Iopamidol, Kidney disease, Renal insufficiency",
author = "Kuhn, {Matthew J.} and Nan Chen and Sahani, {Dushyant V.} and Dan Reimer and {Van Beek}, {Edwin J.R.} and Jay Heiken and So, {George J.}",
year = "2008",
month = "7",
day = "1",
doi = "10.2214/AJR.07.3370",
language = "English (US)",
volume = "191",
pages = "151--157",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "1",

}

TY - JOUR

T1 - The PREDICT study

T2 - A randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure

AU - Kuhn, Matthew J.

AU - Chen, Nan

AU - Sahani, Dushyant V.

AU - Reimer, Dan

AU - Van Beek, Edwin J.R.

AU - Heiken, Jay

AU - So, George J.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - OBJECTIVE. The objective of the PREDICT (patients with renal impairment and diabetes undergoing computed tomography) study was to compare the incidence of contrast-induced nephropathy (CIN) after administration of low-osmolar (iopamidol 370, 796 mOsm/ kg) or isoosmolar (iodixanol 320, 290 mOsm/kg) contrast medium in patients with diabetes and chronic kidney disease undergoing CT. SUBJECTS AND METHODS. Two hundred sixty-three patients with moderate to severe chronic kidney disease (estimated glomerular filtration rate [GFR] = 20-59 mL/ min/1.73 m2) and diabetes mellitus were randomized to receive at least 65 mL of iopamidol 370 or iodixanol 320 for a CT procedure. Serum creatinine levels were measured at baseline and 48-72 hours after contrast administration. CIN was defined as an increase in the serum creatinine level after contrast administration of ≥ 25% from the baseline level. The incidence of CIN in the total study population and the incidence of CIN in patients at increased risk for CIN were compared using Fisher's exact test. RESULTS. Two hundred forty-eight patients were included in the CIN analysis: 125 receiving iopamidol 370 and 123 receiving iodixanol 320. Study population demographics were comparable, as was baseline renal function (estimated GFR = 47.6 mL/min/1.73 m2 for the iopamidol 370 group vs 49.9 mL/min/1.73 m 2 for the iodixanol 320 group; p = 0.16). Increases in the serum creatinine value of ≥ 25% occurred in seven patients (5.6%) receiving iopamidol 370 and in six patients (4.9%) receiving iodixanol 320 (95% CI, -4.8% to 6.3%; p = 1.0). The mean serum creatinine change from the baseline level was 0.04 mg/dL in both groups (analysis of covariance, p = 0.80). In patients with a baseline serum creatinine value of ≥ 2.0 mg/dL, baseline estimated GFR of ≤ 40 mL/min/1.73 m2, or those receiving > 140 mL of contrast medium, the incidence of CIN was low and comparable between the two study groups (p = 1.0 in all instances). CONCLUSION. The incidence of CIN in patients with diabetes and chronic kidney disease receiving IV contrast medium was not significantly different after CT using iopamidol 370 or iodixanol 320.

AB - OBJECTIVE. The objective of the PREDICT (patients with renal impairment and diabetes undergoing computed tomography) study was to compare the incidence of contrast-induced nephropathy (CIN) after administration of low-osmolar (iopamidol 370, 796 mOsm/ kg) or isoosmolar (iodixanol 320, 290 mOsm/kg) contrast medium in patients with diabetes and chronic kidney disease undergoing CT. SUBJECTS AND METHODS. Two hundred sixty-three patients with moderate to severe chronic kidney disease (estimated glomerular filtration rate [GFR] = 20-59 mL/ min/1.73 m2) and diabetes mellitus were randomized to receive at least 65 mL of iopamidol 370 or iodixanol 320 for a CT procedure. Serum creatinine levels were measured at baseline and 48-72 hours after contrast administration. CIN was defined as an increase in the serum creatinine level after contrast administration of ≥ 25% from the baseline level. The incidence of CIN in the total study population and the incidence of CIN in patients at increased risk for CIN were compared using Fisher's exact test. RESULTS. Two hundred forty-eight patients were included in the CIN analysis: 125 receiving iopamidol 370 and 123 receiving iodixanol 320. Study population demographics were comparable, as was baseline renal function (estimated GFR = 47.6 mL/min/1.73 m2 for the iopamidol 370 group vs 49.9 mL/min/1.73 m 2 for the iodixanol 320 group; p = 0.16). Increases in the serum creatinine value of ≥ 25% occurred in seven patients (5.6%) receiving iopamidol 370 and in six patients (4.9%) receiving iodixanol 320 (95% CI, -4.8% to 6.3%; p = 1.0). The mean serum creatinine change from the baseline level was 0.04 mg/dL in both groups (analysis of covariance, p = 0.80). In patients with a baseline serum creatinine value of ≥ 2.0 mg/dL, baseline estimated GFR of ≤ 40 mL/min/1.73 m2, or those receiving > 140 mL of contrast medium, the incidence of CIN was low and comparable between the two study groups (p = 1.0 in all instances). CONCLUSION. The incidence of CIN in patients with diabetes and chronic kidney disease receiving IV contrast medium was not significantly different after CT using iopamidol 370 or iodixanol 320.

KW - Contrast media

KW - Contrast-induced nephropathy

KW - CT

KW - Diabetes mellitus

KW - Iodixanol

KW - Iopamidol

KW - Kidney disease

KW - Renal insufficiency

UR - http://www.scopus.com/inward/record.url?scp=46849097602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46849097602&partnerID=8YFLogxK

U2 - 10.2214/AJR.07.3370

DO - 10.2214/AJR.07.3370

M3 - Article

VL - 191

SP - 151

EP - 157

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 1

ER -